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Pharmacokinetic principles during continuous renal replacement moval is difficult to determine in intermittent dialysis [2]
therapy: Drugs and dosage. Some drugs are removed signifi- but can more easily be estimated in continuous treat-
cantly by continuous renal replacement therapies (CRRTs), and ments [3–5]. Protein binding of the substance togethera substitutional dose is required to prevent underdosing of the
with dialysate and filtrate flow rates determine drugsubstance. This review outlines the basic pharmacokinetic prin-
clearance [6]. The relevance of this extracorporal clear-ciples that determine whether a dose adjustment is required.
Only the free non-protein-bound fraction of a drug can pass ance for overall drug removal, however, largely depends
through the dialyzer membrane. In postdilution hemofiltration on the concurrent drug clearance by residual renal func-
the drug clearance equals the ultrafiltration rate, while in predi- tion, the liver, or other nonrenal mechanisms [7].
lution hemofiltration, the dilution of the blood prior to filtration
needs to be considered when calculating clearance. In continu-
ous hemodialysis, drugs are eliminated by diffusion. Drugs with DRUG CLEARANCE BY CRRT
a higher molecular weight will diffuse more slowly and show
Protein bindinga lower clearance than smaller drugs. The clinical relevance of a
given drug clearance caused by CRRT will mainly depend on Most drugs have a molecular weight up to 500 Daltons.
the competing drug clearance by other elimination pathways. Even larger molecule drugs (for example, vancomycinEven a high clearance for a drug may be irrelevant for overall
at 1448 Daltons) easily pass through typical high-fluxdrug removal if nonrenal clearance pathways provide a much
membranes (pore size 20 to 30,000 Daltons) used forhigher clearance rate. The ideal drug to be removed by CRRT
that requires a dose adjustment has: a low protein binding, continuous dialysis. Only cuprophane and some other
a low volume of distribution, and a low nonrenal clearance. cellulose-based membranes with small pores pose a sig-
Examples include aminoglycosides, vancomycin, fosfomycin, nificant filtration barrier to drugs.
and flucytosine. Even if there are no studies available on the
Because of the pore size of the dialysis membranes,pharmacokinetics of a particular drug during CRRT, knowl-
only substances not bound to plasma proteins will passedge of the basic concepts of drug elimination by continuous
hemodialysis allows a prediction of whether or not a dose through the membrane, either by diffusion or filtration
adjustment will be required during CRRT. [4, 8]. If the basic pharmacokinetic data provide informa-
tion that a drug has a high protein binding (for example,
flucloxacillin protein binding of more than 94% or free
Drugs that are eliminated to a large extent by the fraction ,0.06) [9], no relevant elimination of the sub-
kidneys in individuals with normal renal function require stance by continuous venovenous hemofiltration (CVVH)
or continuous venovenous hemodialysis (CVVHD) cana dose reduction in patients with impaired renal function
be expected. A dose adjustment compared with anuricor anuria. If hemodialysis is initiated, some of the drugs
patients is not required.may be eliminated by dialysis or hemofiltration [1]. To
The free (not protein-bound) fraction of the drug thatavoid underdosing of drugs, an increased daily dose com-
may freely be filtered through the membrane is calcu-pared with that for anuric non-dialyzed patients may be
lated as:required. The purpose of this review is to outline the
general principles determining whether or not a dose Free fraction 5
adjustment is required to compensate for drug elimina-
(1 2 Protein bound fraction) (Eq. 1)tion by continuous renal replacement therapies (CCRTs).
The effect of dialysis or hemofiltration on drug re- Drug clearance using hemofiltration in the
postdilution mode
If hemofiltration is performed in the postdilutionKey words: continuous hemofiltration, hemodiafiltration, drug therapy,
clearance, underdosing during hemodialysis. mode, the ultrafiltrate generated by the procedure con-
tains all drugs that are not protein bound in the same 1999 by the International Society of Nephrology
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Fig. 1. Continuous renal replacement therapy (CRRT) results in different drug clearance rates depending on the treatment modality used. (A)
In postdilution hemofiltration, ultrafiltrate is saturated to 100% compared with the drug concentration in plasma water. The drug clearance equals
the ultrafiltration rate. (B) In predilution hemofiltration, the drug concentration is diluted by substitution fluid prior to entry into the dialyzer,
resulting in a lower saturation of ultrafiltrate compared with the patient’s plasma water. The clearance is lower than the ultrafiltrate flow rate. (C)
In continuous hemodialysis, diffusion of the free non-protein-bound fraction of the drug is variable and depends mainly on the molecular weight
of the drug.
concentration as in the plasma entering the dialyzer to entry into the dialyzer (Fig. 1). Therefore, the drug
through the arterial line (Fig. 1). Clearance of a non- concentration in the plasma entering the dialyzer is lower
protein-bound drug equals the ultrafiltration rate in post- than the plasma drug concentration in the patient’s circu-
dilutional hemofiltration. For protein-bound drugs, the lation. The ultrafiltrate contains the non-protein-bound
ultrafiltration rate has to be multiplied with the free (5 drug in the same concentration as in the plasma water
not protein-bound) fraction: of the blood inside the dialyzer, but this is lower than
in the patient’s blood. This dilutional effect can be calcu-Drug clearancepostdilution HF (ml/min) 5
lated from blood flow/(blood flow 1 substitution rate),
Ultrafiltration rate (ml/min) 3 and the correction must be integrated in the clearance
Equation 2:(1 2 Protein bound fraction) (Eq. 2)
Drug clearancepredilution HF (ml/min) 5Equation 2 disregards that in the arterial blood line,
the drug concentration in plasma water is up to 8% Ultrafiltration rate (ml/min) 3
higher than in plasma alone because plasma proteins
(1 2 Protein bound fraction) 3make up approximately 7 to 8% of the volume of plasma.
Therefore, the drug concentration in ultrafiltrate of a
non-protein-bound drug may even be slightly higher than Blood flow rate
(Blood flow rate 1 substitution rate)
(Eq. 3)
in the plasma entering the dialyzer. This volume effect
of plasma proteins on clearance calculations can gener-
Drug clearance in continuous hemodialysisally be neglected in clinical settings.
Dialysate and blood are separated by a semipermeable
Drug clearance using hemofiltration in dialysis membrane, and diffusion of molecules through
predilution mode this membrane is faster for small substances than for
larger molecules. However, if the time allowed for diffu-If hemofiltration is used in the predilution mode, the
patient’s blood is diluted with a substitute fluid prior sion to take place is very long, eventually the concentra-
Bo¨hler et al: Pharmacokinetics during continuous hemodialysisS-26
in the dialyzer may increase solute clearance by ultrafil-
tration occurring in the first part of the hemofiltration
capillary and backfiltration in the second part of the
capillary. Because larger molecules show a lower diffu-
sion rate, clearance of these substances is expected to
benefit the most from internal filtration and backfiltra-
tion. Filtration/backfiltration increases as higher blood
flow rates are used. The relative importance of these
mechanisms in continuous dialysis on drug clearance and
their clinical relevance for drug dosing have not been
studied thus far.
Hemodiafiltration using dialysis and hemofiltration at
the same time is characterized by a diffusive and convec-
tive component of drug clearance [11]. Drug clearance
in hemodiafiltration may be estimated by calculating
Fig. 2. Drug clearance by diffusion in continuous hemodialysis. Diffu- clearance by convection using Equation 2 and clearancesion of the free non-protein-bound fraction of the drug into the dialysate
by diffusion taken from Figure 2. It should be recognized,depends on molecular weight. Although drug clearance increases with
higher dialysate flow rates, clearance of larger molecules benefits less however, that this is only an approximation because he-
from higher dialysate flow rates. mofiltration may influence diffusion, for example, by
protein layer formation on the blood side of the capillary
or by alterations of diffusion gradients across the semi-
tion of a substance on both sides of the membrane will permeable membrane.
be the same. In this case, clearance rates for small molec-
Drug adsorption to the hemodialysis membraneular-sized substances and larger molecule drugs would
be the same. In contrast, high dialysate flow rates (for Some dialysis membranes may adsorb a substantial
example, 30 liter/hr in intermittent hemodialysis) result amount of drugs to their surface (PAN, AN-69) [12–14].
in a large difference between clearance rates of small In general, dosing guidelines will not account for adsorp-
substances like urea (60 Daltons) or creatinine (113 Dal- tion effects. From a pharmacokinetic point of view, using
tons) and that of larger substances like drugs (mostly drug-adsorbing membranes for CRRT it is not usually
300 to 500 Daltons). recommended because of the poor predictability of ad-
In continuous dialysis, the dialysate flow rate is rela- sorption, which may vary depending on the frequency
tively low (for example, 1.5 liter/hr), resulting in a smaller of dialyzer changes.
difference in clearance rates between large and small
molecules. Figure 2 shows the expected clearance rates
IMPORTANCE OF EXTRACORPORALfor non-protein-bound substances of different molecular
DRUG CLEARANCE FOR TOTALsizes, depending on the dialysate flow rate with the use
DRUG ELIMINATIONof a typical dialyzer used for continuous dialysis at a
The highest clearance that can be achieved with ablood flow of 100 ml/min.
given dialysate or filtrate flow rate is seen in postdilu-Clearance rates given in Figure 2 for a specified molec-
tional hemofiltration of a drug without any protein bind-ular weight and dialysate flow rate can give only a general
ing. This will provide a drug clearance equal to the ultra-guideline to estimate drug clearance in continuous dial-
filtration rate, for example, 25 ml/min (at 1.5 liter ofysis; several other variables need to be considered. If
ultrafiltrate per hour). However, whether or not thisthe drug is partially protein bound, the clearance rate
“high” extracorporal clearance is relevant for overallgiven in Figure 2 needs to be multiplied with free fraction
drug removal requiring dosage adjustment depends on(Equation 1). Moreover, a higher blood flow, a larger
the drug’s pharmacokinetic properties.membrane surface area, a thinner membrane material,
or a different membrane charge may all increase diffu-
Volume of distributionsion of the drug compared with the dialyzer module used
A high volume of distribution (for example, 50 liter/in Figure 2.
kg 5 3759 liters in a 75 kg person) will limit the effective-
Drug clearance using continuous hemodiafiltration ness of drug removal in intermittent hemodialysis. Even
if the drug clearance is as high as the urea clearance (forConvective solute transport by filtration may play a
example, 60 liters per session), only a small proportionrole in drug clearance even if the CRRT is set up to run
(in this example, 60/3759 5 1.6%) of the drug is removedas hemodialysis only [10]. Even in cases of zero net
ultrafiltration, internal ultrafiltration and backfiltration during one dialysis session. In CRRT, the volume of
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distribution is less important because all elimination path- plasma levels above the minimal inhibitory concentra-
tions of the bacteria, whereas side effects occur if highways—renal, nonrenal, or extracorporal—have to clear
the same volume of distribution. Therefore, the relative peak concentrations are reached with use of high single
doses. In these drugs it may be useful to shorten thecontribution of the clearance rates of all elimination
pathways in CRRT is the key determinant to consider. dosing intervals instead of increasing the individual dose.
Estimation of required supplemental doseCompetition of elimination pathways
In an anuric non-dialyzed patient, nonrenal clearance Equations 4 and 5 permit the estimation of both meth-
ods of dose adjustment in CRRT patients based on basicoccurs mainly by the hepatic route. To estimate the clini-
cal relevance of drug clearance by CRRT, it has to be pharmacokinetic parameters. The equations rely on the
viewed in relationship to the competing nonrenal clear- principles of clearance calculation and competing elimi-
ance [7]. The identical high drug clearance by CRRT nation pathways, as outlined earlier in this article. The
(for example, 25 ml/min) for one substance may be very pharmacokinetic parameters of the drug required in the
important for drug dosing. In another substance, the equations are: (a) clearance in anuric non-dialyzed pa-
same clearance value can be clinically irrelevant because tients 5 nonrenal clearance, (b) half-life of the drug in
the hepatic clearance is much higher. anuric non-dialyzed patients, (c) dosing interval in anuric
Depending upon the drug, nonrenal clearance may be non-dialyzed patients, (d) dose in anuric non-dialyzed
as low as 5 ml/min (for example, in vancomycin) [15] or patients, and (e) protein binding to estimate CRRT drug
as high as 350 ml/min (for example, acetaminophen) [16]. clearance. Because all of the parameters used in the
A CRRT clearance, for example, of 15 ml/min, increases equations are estimates, this approach should only be
the total vancomycin clearance fourfold, and a corre- used if no established guidelines for dose adjustment in
spondingly higher dose is required. In the case of acet- CRRT treatments are available based on clinical studies
aminophen, which shows no protein binding, even a in intensive care patients. Whenever feasible, the mea-
CRRT clearance of 25 ml/min will not increase the total surement of drug concentrations should be used to guide
drug clearance significantly. Because of overwhelming the therapy.
hepatic clearance, the dose does not need to be modified Equation 4 shows the estimation of a shorter dosing
during CRRT. interval during CRRT. The individual dose remains un-
changed compared with anuric non-dialyzed patients.
ADJUSTMENT OF DRUG DOSE DURING Interval(CRRT) 5 Interval(anuria) *
CRRT TREATMENT
Clearanceanuria
Clearanceanuria 1 ClearanceCCRT
(Eq. 4)The intensive care patient requiring CRRT is at risk
not only for drug accumulation and drug overdose be-
Equation 5 shows the estimation of higher dose duringcause of acute renal failure, but also for underdosing that
CRRT (the same as the supplemental dose due to CRRTmay be life threatening, such as in the case of insufficient
drug removal plus the dose in an anuric patient). Theantibiotic treatment. A supplemental dose correspond-
dosing interval remains unchanged compared with anuricing to the amount of drug removed by CRRT also may
non-dialyzed patients:be required for the anuric non-dialyzed patient.
Dose(CRRT) 5 Dose(anuria) *Higher dose or shorter dosing interval
Depending on the drug, it may be more appropriate
to shorten the dosing interval or to increase the dose. In 31 1 1ClCRRTClanuria/2
Interval
Halflife 24 (Eq. 5)aminoglycosides, the bactericidal effect correlates with
peak concentrations [17]. In anuric non-dialyzed pa-
tients, only very low aminoglycoside doses can be used
FUTURE PERSPECTIVESin order to avoid toxic side effects. These low doses
result in low peak levels and thus carry the risk of not For the majority of drugs, no studies are available that
investigate pharmacokinetics in CRRT patients. Becausebeing efficient in terms of bacterial killing. After begin-
ning CRRT, it is preferable to increase the single daily of the numerous variations of CRRT modalities, it is
unlikely to find dosing guidelines that fit the individualdose to achieve higher peak levels, while at the same
time, CRRT treatment helps to decrease the drug levels patient as well as the individual method of treatment.
Current methods for estimating the supplemental dose,to low trough concentrations and thereby reduces the
risk of side effects. as outlined earlier in this article, require a careful and
time-consuming search for basic pharmacokinetic drugIn contrast, the efficacy of other antibiotics (for exam-
ple, b-lactam antibiotics) may be related to constant data. In this issue of Kidney International, a simple new
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